Cartherics is pioneering the development of ‘off-the-shelf’ immunotherapy products for cancer using novel, specially selected, cell lines to create haplotype induced pluripotent stem cells (iPSCs) and other iPSC lines, that can be infinitely expanded. These iPSCs are being gene edited and differentiated to become cytotoxic T cells, NK cells and macrophages with multiple targeting receptors and gene edits, for use in clinical trials, initially, for treatment of relapsed ovarian and gastric cancers.
The Cartherics team is closely aligned with leading cancer research groups, including The Peter MacCallum Cancer Centre (PMCC) and their partners at the new Victorian Comprehensive Cancer Centre (VCCC); together with a strong research base at ARMI and access to all Research Platform facilities at Monash University and its affiliated clinical institutes of Monash Health.
As part of the Higher Degree Training Program, Cartherics offers high calibre eligible students Masters and PhD research programs of study that include world-class research training, as well as opportunities to develop diverse commercialisation and clinical translation skills that will benefit their future career. The Cartherics Higher Degree Programs centre on medical research specifically combining stem cells and immunotherapy to cure cancer.
Cartherics PhD Students are enrolled through Monash University in the prestigious Monash University Doctoral Program.
ARMI Masters of Biotechnology Students can undertake the Research component of their degree at Cartherics.
Cartherics Honours Degree Students can be enrolled through the Faculty of Science (BSc Hons Program), the ARMI (B Med Sci Hons Program) or the Faculty of Medicine (Bachelor of Medical Science Hons Program).